Advances in precision oncology have transformed the way metastatic lung cancer is treated. Instead of relying only on chemotherapy, doctors increasingly tailor treatment based on specific genetic alterations driving tumour growth.
One of the most important molecular targets in lung cancer is the EGFR gene (Epidermal Growth Factor Receptor). Certain EGFR mutations can cause uncontrolled cell growth, leading to the development and progression of non-small cell lung cancer (NSCLC).
For patients with metastatic EGFR-mutated lung cancer, targeted therapies known as EGFR inhibitors have significantly improved treatment outcomes and disease control.
Topics Covered
Topics Covered
Topics Covered
Topics CoveredWhat Are EGFR Mutations in Lung Cancer?
Are EGFR Mutations in Lung Cancer?
EGFR mutations are genetic alterations in the epidermal growth factor receptor gene, which plays an essential role in regulating cell growth and survival.
When these mutations occur, the receptor can become permanently activated, triggering continuous signals that drive tumour growth.
EGFR mutations are particularly common in:
- patients with adenocarcinoma of the lung
- never-smokers or light smokers
- certain populations, including Asian patients
In patients with metastatic NSCLC, identifying EGFR mutations is critical because it allows doctors to prescribe targeted therapies designed specifically for these alterations.
The Most Common EGFR Mutations
Several EGFR mutations have been identified, but two mutations account for the majority of cases.
| EGFR Mutation | Frequency | Clinical Significance |
|---|---|---|
| Exon 19 deletion | ~45% of EGFR mutations | Highly sensitive to EGFR targeted therapies |
| L858R mutation (Exon 21) | ~40% of EGFR mutations | Also responsive to targeted treatment |
| Less common EGFR mutations | Smaller percentage | May require specialised treatment approaches |
These mutations activate signalling pathways that promote tumour growth. Targeted therapies work by blocking these signals.
Why Molecular Testing Is Essential
Because EGFR mutations cannot be detected through imaging or routine pathology alone, molecular testing is required.
Testing is typically performed on tumour tissue obtained through biopsy. In some cases, liquid biopsy using circulating tumour DNA can also identify EGFR mutations.
Comprehensive molecular testing helps identify:
- EGFR mutations
- other targetable alterations such as ALK, ROS1 or MET
- biomarkers that guide treatment decisions
Identifying these mutations ensures that patients receive the most appropriate targeted therapy.
EGFR-Targeted Therapies
EGFR-targeted therapies are designed to block abnormal EGFR signalling and slow cancer growth.
These drugs are known as EGFR tyrosine kinase inhibitors (EGFR TKIs).
Unlike chemotherapy, which affects both healthy and cancerous cells, targeted therapies act specifically on cancer cells carrying the EGFR mutation.
EGFR inhibitors are typically taken as oral medications, making them convenient for long-term treatment.
For many patients with metastatic EGFR-mutated NSCLC, targeted therapy is now the preferred initial treatment approach.
Treatment Strategy for Metastatic EGFR-Mutated Lung Cancer
Treatment planning for metastatic EGFR-positive lung cancer is usually discussed within a multidisciplinary team (MDT) involving medical oncologists, radiologists and other specialists.
Management strategies may include:
- EGFR-targeted therapy as first-line treatment
- monitoring response with imaging and molecular testing
- adjusting treatment if resistance mutations develop
- consideration of clinical trials for new targeted therapies
This personalised approach helps optimise treatment outcomes while maintaining quality of life.
Side Effects of EGFR Inhibitors
Although targeted therapies are generally well tolerated, EGFR inhibitors can cause side effects.
Common side effects include:
- skin rash
- diarrhoea
- fatigue
- nail or skin changes
These side effects are often manageable with supportive treatment and close monitoring by the oncology team.
Early recognition and management of treatment-related toxicities are important to ensure patients can continue therapy safely.
Precision Oncology and the Future of Lung Cancer Treatment
The discovery of EGFR mutations has transformed the treatment landscape for lung cancer.
Instead of a one-size-fits-all approach, doctors can now match therapies to the genetic characteristics of each patient’s tumour.
Ongoing research continues to explore:
- next-generation EGFR inhibitors
- resistance mechanisms to targeted therapies
- combination treatment strategies
These advances are helping improve outcomes for patients with metastatic EGFR-mutated lung cancer.
Conclusion
Common EGFR mutations represent one of the most important molecular drivers of metastatic non-small cell lung cancer.
Through comprehensive molecular testing and the use of EGFR-targeted therapies, oncologists can now offer personalised treatment strategies that significantly improve disease control for many patients.
As precision oncology continues to evolve, targeted therapies for EGFR-mutated lung cancer remain a cornerstone of modern lung cancer treatment and contribute to improving lung cancer survival rates for many patients.
Support and Follow-Up Care
Dr Papadatos-Pastos and his team provide ongoing support beyond medical treatment.
Patients receive clear communication, psychological care and access to nutrition, physiotherapy and symptom-management services.
Regular follow-up ensures early detection of recurrence and long-term wellbeing.
Book a Consultation
If you or someone close to you has been diagnosed with lung cancer, early consultation with a specialist can make a real difference. Appointments are available at several London clinics.
Faq
Answers to Common Questions
Answers to common questions about metastatic EGFR-mutated lung cancer, including how EGFR mutations are identified and how targeted EGFR therapies are used in modern lung cancer treatment.
The most common EGFR mutations are exon 19 deletions and the L858R mutation in exon 21.
EGFR mutations occur in approximately 10–15% of non-small cell lung cancer cases in Western populations.
EGFR mutations are identified through molecular testing performed on tumour tissue or circulating tumour DNA.
EGFR tyrosine kinase inhibitors (EGFR TKIs) are targeted therapies used to treat cancers with EGFR mutations.
Yes. Over time, some tumours develop resistance mutations, which may require changes in treatment strategy.
